KWS BioTest has a new Head of Business Development

KWS BioTest has a new Head of Business Development

Bristol, UK, 7th July 2014 - KWS BioTest, a CRO offering a range of services spanning preclinical development from early cell biology, through efficacy models to clinical sample analysis, has today announced that Simon Johns has been appointed as their new Head of Business Development.

Simon has a scientific background in medical microbiology, as well as 20 years' international experience supporting pharmaceutical and biotechnology clients in all areas of early discovery, preclinical and clinical development. He has worked in senior management positions for three major global CROs, providing solutions for clients throughout the world.

Dr Robin Brown, CEO of KWS BioTest, commented: "It's a pleasure to welcome Simon to KWS as our Head of Business Development. His appointment will considerably strengthen our Business Development team and underlines our ambition to accelerate the growth of KWS."

Simon Johns commented: "I am very impressed with the high quality of work KWS BioTest delivers for its clients across a wide range of scientific areas including immunology, inflammation and infection. I look forward to helping the company continue its strong business growth throughout Europe and the rest of the world, and to further establishing KWS BioTest as the partner of choice for clients in early discovery, preclinical and clinical product development."

Suggested Articles

Dubbed “Project Nightingale,” the efforts were announced amid concerns and federal inquiries into the data’s safekeeping and patient consent for use.

Independent site management organization Panthera Biopartners has kick-started its first clinical trial in the U.K.

WIRB-Copernicus Group’s clinical services division bought out trial consultancy firm Waife & Associates as it looks to boost its management services.